November 2020 Foundation eNews

lesturnerAdvocacy, Foundation eNews, Home Page, Support Services

Empowering through ALS Education We are excited to launch our new online learning series aimed at empowering our ALS community through the latest information and insights. Educational webinars and interactive Q&A’s covering a diverse array of topics, from telemedicine to …

Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS

lesturnerFoundation Blog, Home Page, Research News

We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020)  in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …

October 2020 Foundation eNews

lesturnerFoundation eNews, Home Page, Support Services

Join our 10th Annual Les Turner Symposium on ALS – Monday, November 9 Registration is now open for our 10th Annual Symposium, hosted by our own Les Turner ALS Center at Northwestern Medicine. This year’s event will be held virtually on …

Advocacy Announcement: ALS Disability Insurance Access Act

lesturnerAdvocacy, Foundation Blog, Home Page

Foundation Blog: Advocacy The Les Turner ALS Foundation has joined with several other national ALS patient advocacy organizations (ALS Association, I AM ALS, Muscular Dystrophy Association and Team Gleason) in a letter to U.S. House of Representatives’ leadership requesting that …

Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression

lesturnerFoundation Blog, Home Page, Research News

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …